THANK YOU FOR SUBSCRIBING
QP-Insights is a comprehensive web platform for managing, storing, and quantitatively analyzing medical images and other clinical data.
FREMONT, CA: “As a company looking to speed up the early detection of cancer and other diseases, we are acutely aware of the important role that our research, healthcare, and pharmaceutical partners play in ensuring the technology actually gets used to treat real-life patients. What is so exciting to us about QP-Insights is that it marks a milestone in how we’re able to use already existing clinical data sources from the healthcare sector to further develop our products with predictive functionality, as well as in the ease with which pharmaceutical researchers can use the technology itself in research going forward,” says Angel Alberich-Bayarri, Co-founder and CEO of Quibim.
Quibim, a global pioneer in imaging biomarkers for precision medicine, unveiled QP-Insights. This new product allows researchers to use clinical imaging data throughout drug development programs. Leading biopharmaceutical companies and European research consortiums are already using the platform.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
QP-Insights was developed in collaboration with researchers to provide a comprehensive platform for storing, accessing, and analyzing medical images and other multi-omics data. With the increasing importance of real-world data (RWD) in drug development efforts, a robust platform for extracting insights from RWD is critical to realizing its potential.
Researchers will have access to Quibim's data processing tools (such as image harmonization and annotation). It is the foundation upon which AI-powered tools can be built to speed up the development of precision medicines. It is being rolled out globally and has been meticulously designed to comply with all applicable international data privacy and cybersecurity regulations and standards, including the European Union's General Data Protection Regulation (GDPR), the United States Health Insurance Portability and Accountability Act (HIPAA), and GAMP, or Good Automated Manufacturing Practice.
In addition to being an all-in-one data processing and management solution, QP-Insights will serve as the platform for imaging-based biomarker algorithms, allowing researchers to stratify and identify individuals most likely to benefit or experience side effects from investigational medicines earlier.
The platform has already been tested and trusted by leading biopharmaceutical companies, and it serves as the foundation for nine EU-wide research consortiums, including the European Federation for Cancer Images (EUCAIM), which is tasked with assisting in meeting the targets outlined in Europe's Beating Cancer Plan.
More in News